RhumbLine Advisers
FHTX icon

RhumbLine Advisers’s Foghorn Therapeutics FHTX Stock Holding History

RhumbLine Advisers’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$149K Buy
41,832
+2,250
+6% +$11.8K ﹤0.01% 3390
2026
Q2 		$193K Buy
39,582
+77
+0.2% +$342 ﹤0.01% 3297
2026
Q1 		$189K Sell
39,505
-612
-2% -$3.36K ﹤0.01% 3149
2025
Q4 		$217K Sell
40,117
-3,606
-8% -$16.3K ﹤0.01% 3145
2025
Q3 		$214K Sell
43,723
-442
-1% -$2.34K ﹤0.01% 3190
2025
Q2 		$208K Buy
44,165
+7,920
+22% +$33.1K ﹤0.01% 3212
2025
Q1 		$132K Sell
36,245
-139
-0.4% -$634 ﹤0.01% 3295
2024
Q4 		$172K Buy
36,384
+3,049
+9% +$22.2K ﹤0.01% 3269
2024
Q3 		$310K Sell
33,335
-2,575
-7% -$18.6K ﹤0.01% 3006
2024
Q2 		$206K Buy
35,910
+9,171
+34% +$54.6K ﹤0.01% 3205
2024
Q1 		$179K Buy
26,739
+778
+3% +$4.32K ﹤0.01% 3229
2023
Q4 		$167K Sell
25,961
-465
-2% -$2.01K ﹤0.01% 3270
2023
Q3 		$132K Buy
26,426
+999
+4% +$7.7K ﹤0.01% 3365
2023
Q2 		$179K Buy
25,427
+113
+0.4% +$790 ﹤0.01% 3291
2023
Q1 		$157K Sell
25,314
-437
-2% -$2.86K ﹤0.01% 2794
2022
Q4 		$164K Buy
25,751
+973
+4% +$7.34K ﹤0.01% 2834
2022
Q3 		$213K Buy
24,778
+1,701
+7% +$21.9K ﹤0.01% 2872
2022
Q2 		$314K Buy
23,077
+401
+2% +$5.18K ﹤0.01% 2728
2022
Q1 		$345K Buy
22,676
+3,223
+17% +$44.2K ﹤0.01% 2593
2021
Q4 		$445K Buy
19,453
+979
+5% +$14.1K ﹤0.01% 2558
2021
Q3 		$257K Buy
18,474
+2,815
+18% +$31.2K ﹤0.01% 2828
2021
Q2 		$167K Buy
+15,659
New +$171K ﹤0.01% 2936

Other funds holding FHTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

RhumbLine Advisers's FHTX Position: Q3 2026 in Review

RhumbLine Advisers increased its Foghorn Therapeutics (FHTX) stake by 5.7% in Q3 2026, buying an estimated $11.8K and bringing the position to 41,832 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #3390.

RhumbLine Advisers first reported a position in FHTX in Q2 2021 and has held it in 22 quarters since. The position peaked at $445K in Q4 2021. 44 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

  • RhumbLine Advisers held 41,832 shares of Foghorn Therapeutics worth $149K as of Q3 2026.
  • RhumbLine Advisers bought 2,250 Foghorn Therapeutics shares in Q3 2026, an estimated $11.8K.
  • Foghorn Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3390 holding.
  • RhumbLine Advisers first reported a position in Foghorn Therapeutics in Q2 2021 and has held it in 22 quarters since.
  • RhumbLine Advisers's Foghorn Therapeutics position peaked at $445K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.